The University of California-San Francisco has a long history of involvement in cooperative group efforts in general and in Cancer and Leukemia Group B in particular. This application describes, in detail, the scope and breadth of cancer research at the UCSF Helen Diller Family Comprehensive Cancer Center as well as the participation in and leadership positions held by UCSF investigators within CALGB. This application is divided into three sections: I. Major Research Interests/Capabilities of the University of California - San Francisco Cancer Center, II. Organization employed for institutional Group participation and III. Scientific and Clinical Contributions to the Group and Plans for the award period. This is a new U10 application for UCSF. I. The University of California-San Francisco Helen Diller Family Comprehensive Cancer Center (UCSFHDFCCC) is an NCI-designated matrix center involving a wide range of interdisciplinary research personnel in the laboratory, clinical, and population sciences. In total, the UCSF-HDFCCC integrates the activities of 331 members (247 program members, 23 members, 42 associate members, and 19 affiliate members) working at four major campus and hospital locations. II. Robust participation in CALGB related activities is a high priority in the UCSF-HDFCCC. As such, a permanent CALGB infrastructure has been created that consists of a principal investigator, internal advisory board, a program manager, regulatory analyst, investigational pharmacist and clinical research coordinators. III. UCSF CALGB members have served or are serving as chairs or co-chairs of 7 currently active protocols and have served as chairs of 6 other protocols during the past 8 years. Further, 8 protocols proposed by UCSF investigators have been approved by the Executive Committee and will be open to accrual within a 12-month time frame. In addition to this scientific leadership, two CALGB committees (GU and Transplant) are chaired by UCSF faculty. These are detailed in this application.
|Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050|
|Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442|
|Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2017) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int :|
|Mehrotra, Shailly; Sharma, Manish R; Gray, Elizabeth et al. (2017) Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J 19:1411-1423|
|Dickler, Maura N; Barry, William T; Cirrincione, Constance T et al. (2016) Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 34:2602-9|
|Wetzler, Meir; Watson, Dorothy; Stock, Wendy et al. (2014) Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 99:111-5|
|Walker, Alison; Mrózek, Krzysztof; Kohlschmidt, Jessica et al. (2013) New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. Genes Chromosomes Cancer 52:385-401|